GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acer Therapeutics Inc (OTCPK:ACER) » Definitions » Current Deferred Taxes Liabilities

Acer Therapeutics (Acer Therapeutics) Current Deferred Taxes Liabilities : $0.00 Mil (As of Jun. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Acer Therapeutics Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Acer Therapeutics's current deferred tax liabilities for the quarter that ended in Jun. 2023 was $0.00 Mil.

Acer Therapeutics Current Deferred Taxes Liabilities Historical Data

The historical data trend for Acer Therapeutics's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acer Therapeutics Current Deferred Taxes Liabilities Chart

Acer Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Acer Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Acer Therapeutics Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of Acer Therapeutics's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Acer Therapeutics (Acer Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
300 Washington Street, One Gateway Center, Suite 351, Newton, MA, USA, 02458
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
Executives
Chris Schelling director, officer: President and Chief Executive C/O ACER THERAPEUTICS INC., 222 THIRD STREET, CAMBRIDGE MA 02142
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Tanya Hayden officer: Chief Operating Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Adrian W Quartel officer: Chief Medical Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Bernard H Paul officer: Chief People Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Jefferson E Davis officer: Chief Business Officer 300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
John Michael Dunn director C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Donald Joseph officer: Chief Legal Officer and Secy C/O KALOBIOS PHARMACEUTICALS, INC., 260 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Michael Klopp officer: Chief Technology Officer ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Matthew Seibt officer: Chief Commercial Officer ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Harry S Palmin officer: Chief Opp. and Financial Offr C/O NOVELOS THERAPUETICS, INC., ONE GATEWAY CENTER,SUITE 504, NEWTON MA 02458
William T. Andrews officer: Chief Medical Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Jason Amello director 500 KENDALL STREET, CAMBRIDGE MA 01824
Salma Jutt-eghbali officer: Chief Commercial Officer ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458

Acer Therapeutics (Acer Therapeutics) Headlines

From GuruFocus

Is Acer Therapeutics Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 12-02-2022

Acer Therapeutics Announces $1.5M Private Placement

By Value_Insider Value_Insider 11-30-2022